Senior Leadership: This year, Dr. Thompson, an internationally recognized leader in cancer research,replaced Dr. John Click as Director of the Cancer Center. Dr. Thompson appointed Dr. Caryn Lermanto assume his former position as Deputy Director of the Cancer Center and Co-Principal Investigator ofthe Cancer Center Core Grant. Dr. Lerman, the former Associate Director for Cancer Control andPopulation Science, is a scientific leader in cancer control and tobacco related research. In addition,Dr. Lewis Chodosh, a scientific leader in cancer biology, assumed Dr. Thompson's former position asChair of the Cancer Biology Department, and replaced Dr. Mark Greene as the Cancer Center'sAssociate Director for Fundamental Research. With the departure of Dr. Stephen Emerson, Dr. GarrettBrodeur was appointed the Acting Associate Director for Clinical Research; an active search for anAssociate Director for Clinical Research is underway.Drs. Thompson, Lerman, Chodosh and Brodeur form the senior leadership of the Cancer Center. Thisgroup, representing the broad range of expertise in basic science, translational and clinical research,and population science research, is responsible for examining the ongoing initiatives and futuredirections of the Cancer Center at the global level. Drs. Thompson and Lerman meet on a weeklybasis, and the senior leadership group interacts formally on a monthly basis, as well as informallythrough telephone and email. This process ensures timely and proactive decision-making, as well ascohesiveness in direction. The Senior Leadership has been instrumental in reviewing and responding tothe feedback from the competitive Core Grant review process, identifying new leaders for the ExecutiveCommittee and Cancer Center Programs, and reviewing the Core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-33
Application #
7726709
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$237,113
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32

Showing the most recent 10 out of 1047 publications